BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pierre Fabre Medicament readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Pierre Fabre Medicament's drugs r
 un\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05270044-1996@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Binimetinib: Phase 3 readout est. (NCT05270044)
DESCRIPTION:Binimetinib\, phase 3\, Melanoma.\nStudy: Adjuvant Encorafenib 
 and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.\nEsti
 mated primary completion: 31 March 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/binimetinib#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT05270044
URL:https://assetmemo.bio/drug/binimetinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06567015-2745@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20271120
DTEND;VALUE=DATE:20271121
SUMMARY:STX-241: Phase 1/2 readout est. (NCT06567015)
DESCRIPTION:STX-241\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Study
  of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EG
 FR TKIs\nEstimated primary completion: 20 November 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/stx-241#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06567015
URL:https://assetmemo.bio/drug/stx-241#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06043817-2746@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20291201
DTEND;VALUE=DATE:20291202
SUMMARY:Elticertinib: Phase 1/2 readout est. (NCT06043817)
DESCRIPTION:Elticertinib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: 
 First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advan
 ced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 2
 0 Insertion Mutations\nEstimated primary completion: 1 December 2029. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/elticertinib#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT06043817
URL:https://assetmemo.bio/drug/elticertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06669117-2792@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20301021
DTEND;VALUE=DATE:20301022
SUMMARY:VERT-002: Phase 1/2 readout est. (NCT06669117)
DESCRIPTION:VERT-002\, phase 1/2.\nStudy: FIH Trial of VERT-002 in Patients
  With Locally Advanced or Metastatic Solid Tumors With MET Alterations\nEs
 timated primary completion: 21 October 2030. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/vert-002#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06669117
URL:https://assetmemo.bio/drug/vert-002#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
